We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group.
- Authors
De Pauw, Ben E.; Deresinski, Stanley C.; Feld, Ronald; Lane-Allman, Elizabeth F.; Donnelly, J. Peter; De Pauw, B E; Deresinski, S C; Feld, R; Lane-Allman, E F; Donnelly, J P
- Abstract
<bold>Objective: </bold>To compare piperacillin and tobramycin with ceftazidime alone for the empiric treatment of fever in the neutropenic patient without evidence of skin infections or anaerobic infections.<bold>Design: </bold>A multicenter, randomized, controlled trial.<bold>Patients: </bold>876 febrile, neutropenic episodes in 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation.<bold>Interventions: </bold>Patients received either intravenous ceftazidime (2 g every 8 h) or piperacillin (12 to 18 g/d in 4 to 6 divided doses plus tobramycin (1.7 to 2.0 mg/kg body weight every 8 h). Treatment could be modified at any time at the discretion of the investigator.<bold>Measurements: </bold>Percentage of satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events.<bold>Results: </bold>As a single agent, ceftazidime was as effective as the combination of piperacillin and tobramycin (62.7% satisfactory responses compared with 61.1%; odds ratio, 1.07%; 95% Cl, 0.79 to 1.44; P > 0.2). Equivalent responses were also obtained in episodes of profound neutropenia (odds ratio, 0.76; Cl, 0.43 to 1.33; P > 0.2). Infectious mortality was 6% for ceftazidime and 8% for the combination therapy. Eradication of the infecting organisms was achieved in 79% of bacteremic episodes treated with ceftazidime compared with 68% of the episodes treated with the combination therapy (odds ratio, 1.76; Cl, 0.92 to 3.38; P = 0.08), and rates for gram-negative rod bacteremia were also similar (95% compared with 77%; odds ratio, 5.25; Cl, 1.0 to 27.5; P = 0.03). Superinfections developed in 38 episodes in each group. An adverse event occurred in 8% of episodes treated with ceftazidime compared with 20% of episodes treated with combination therapy (P < 0.001).<bold>Conclusion: </bold>Ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia.
- Subjects
PIPERACILLIN; TOBRAMYCIN; EMPIRICAL medicine; NEUTROPENIA; PATIENTS
- Publication
Annals of Internal Medicine, 1994, Vol 120, Issue 10, p834
- ISSN
0003-4819
- Publication type
journal article
- DOI
10.7326/0003-4819-120-10-199405150-00004